| Followers | 200 |
| Posts | 25596 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Sunday, November 20, 2022 1:02:44 PM
He did not say Top Line Data for other cancers. Those were your words.
There is data for other cancers. You do understand that also, others were discussing the new regulations and you changed the subject.
For an APPROVED drug, companies can work with the insurance companies to get coverage for off-label coverage based solely on real world data, which is not clinical trial data, but things like hospital records and economic data as well. The company does potentially have and likely will continue to develop data for such patients. Real World Data is not a clinical trial.
Likewise, for the expansion of a label, going forward, real world data can be used with the FDA and other regulators. The 21st Century Cures Act’s entire purpose was to expedite getting these drugs to patients and providing affordable access to new breakthrough drugs more quickly and to cut through unnecessary delays and red tape. There is a particular focus on expediting access to drugs targeted at genes and protein targets and cell therapies.
It’s all new. But that is what is happening, NOW.
There is data for other cancers. You do understand that also, others were discussing the new regulations and you changed the subject.
For an APPROVED drug, companies can work with the insurance companies to get coverage for off-label coverage based solely on real world data, which is not clinical trial data, but things like hospital records and economic data as well. The company does potentially have and likely will continue to develop data for such patients. Real World Data is not a clinical trial.
Likewise, for the expansion of a label, going forward, real world data can be used with the FDA and other regulators. The 21st Century Cures Act’s entire purpose was to expedite getting these drugs to patients and providing affordable access to new breakthrough drugs more quickly and to cut through unnecessary delays and red tape. There is a particular focus on expediting access to drugs targeted at genes and protein targets and cell therapies.
It’s all new. But that is what is happening, NOW.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
